Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes
Type 2 Diabetes Mellitus

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus
Eligibility Criteria
Inclusion criteria :
- Patients with type 2 diabetes mellitus diagnosed at least 1 year before the screening visit
Patient treated for at least 3 months prior to screening visit with one of following OADs at a stable dose of at least usual maintenance dose as described in the label
- a biguanide (metformin hydrochloride);
- a thiazolidinedione (TZD) (pioglitazone hydrochloride);
- an alpha-glucosidase inhibitor (alpha-GI) (acarbose, voglibose or miglitol);
- or a glinide (nateglinide, repaglinide or mitiglinide);
- Signed written informed consent
Exclusion criteria:
- At screening HbA1c <7% or >9.5%;
- At screening: fasting plasma glucose >250 mg/dL (>13.9 mmol/L);
- Use of any glucose-lowering agent(s) other than the authorized patient's background treatment defined in I02 (as given in inclusion critieria) within 3 months prior to screening;
- Type 1 diabetes mellitus;
- Women of childbearing potential with no effective contraceptive method;
- Pregnancy or lactation;
Laboratory findings at the time of screening:
- Amylase and/or lipase >3 times the upper limit of the normal laboratory range (ULN);
- ALT >3 ULN;
- Any contra-indication to the patient's background oral anti-diabetic treatment;
- History of acute or chronic pancreatitis, pancreatectomy, stomach/gastric surgery, inflammatory bowel disease;
- Personal or immediate family history of medullary thyroid cancer (MTC) or genetic conditions that predispose to MTC (eg, multiple endocrine neoplasia syndromes);
- Any previous treatment with lixisenatide (eg, participation in a previous study with lixisenatide) or any other GLP1 receptor agonist.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Sites / Locations
- Investigational Site Number 392335
- Investigational Site Number 392325
- Investigational Site Number 392328
- Investigational Site Number 392326
- Investigational Site Number 392327
- Investigational Site Number 392310
- Investigational Site Number 392336
- Investigational Site Number 392314
- Investigational Site Number 392334
- Investigational Site Number 392304
- Investigational Site Number 392306
- Investigational Site Number 392307
- Investigational Site Number 392301
- Investigational Site Number 392312
- Investigational Site Number 392302
- Investigational Site Number 392324
- Investigational Site Number 392331
- Investigational Site Number 392332
- Investigational Site Number 392329
- Investigational Site Number 392322
- Investigational Site Number 392333
- Investigational Site Number 392330
- Investigational Site Number 392320
- Investigational Site Number 392303
- Investigational Site Number 392311
- Investigational Site Number 392316
- Investigational Site Number 392319
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Experimental
Lixisenatide + Biguanide
Lixisenatide + TZD
Lixisenatide + alpha-GI
Lixisenatide + Glinide
52-week treatment with Lixisenatide in combination with biguanide (usual maintenance dose in the label)
52-week treatment with lixisenatide in combination with TZD (usual maintenance dose in the label)
52-week treatment with Lixisenatide in combination with alpha-GI (usual maintenance dose in the label)
52-week treatment with Lixisenatide in combination with glinide (usual maintenance dose in the label)